List of Excipients in Branded Drug AMMONUL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	AMMONUL	sodium phenylacetate and sodium benzoate	0187-0010	HYDROCHLORIC ACID
Bausch Health US LLC	AMMONUL	sodium phenylacetate and sodium benzoate	0187-0010	SODIUM HYDROXIDE
Bausch Health US LLC	AMMONUL	sodium phenylacetate and sodium benzoate	0187-0010	WATER
Ucyclyd Pharma Inc	AMMONUL	sodium phenylacetate and sodium benzoate	62592-720	HYDROCHLORIC ACID
Ucyclyd Pharma Inc	AMMONUL	sodium phenylacetate and sodium benzoate	62592-720	SODIUM HYDROXIDE

AMMONUL Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

AMMONUL is an intravenous ammonia-scavenging product containing equal concentrations of sodium phenylacetate and sodium benzoate. Its commercial opportunity is driven less by novel active-ingredient chemistry than by formulation execution: lower sodium burden, ready-to-use presentation, pediatric usability, improved stability, and reduced infusion complexity. The product’s key technical constraint is that both active ingredients are administered as highly concentrated sodium salts, creating osmolarity, sodium-load, tolerability, and dilution challenges.[1]

What is AMMONUL and how does its formulation work?

AMMONUL is an intravenous treatment for acute hyperammonemia associated with urea-cycle disorders. Sodium phenylacetate and sodium benzoate provide alternative nitrogen-excretion pathways. The product is administered with intravenous dextrose and other supportive measures under specialist supervision.[1]

Attribute	AMMONUL profile
Active ingredients	Sodium phenylacetate and sodium benzoate
Concentration	100 mg/mL of each active ingredient
Dosage form	Sterile intravenous concentrate
Primary use	Acute hyperammonemia in urea-cycle disorders
Patient population	Pediatric and adult patients, including neonates
Route	Intravenous infusion after dilution
Key formulation issue	High sodium and osmotic load
Diluent	Typically 10% dextrose injection, subject to clinical requirements
Preservative strategy	Single-dose sterile presentation without a conventional antimicrobial preservative
Regulatory category	Orphan drug product for a rare metabolic disorder

The formulation uses water for injection as the principal inactive component, with pH adjustment as required. The label instructs dilution before administration and sets handling requirements designed to control precipitation, concentration, and infusion exposure.[1]

What excipients are used in AMMONUL?

AMMONUL has a minimal excipient system. The commercial formulation is built around:

1. Water for injection.
2. pH adjustment, generally using hydrochloric acid.
3. A sterile single-dose container.
4. An external infusion diluent, commonly dextrose solution.

This low-excipient design reduces risks associated with benzyl alcohol, parabens, sulfites, polysorbates, and other excipients that can create additional safety or compatibility issues in neonates and critically ill patients.

The absence of a complex excipient matrix has two commercial consequences. First, the product has a relatively simple qualitative formulation from a composition-of-matter perspective. Second, differentiation depends on quantitative formulation engineering, container closure, infusion presentation, and administration workflow rather than on a broad inactive-ingredient claim set.

Why is water for injection strategically important?

Water for injection is not a passive choice in this product. The formulation contains two highly soluble sodium salts at high concentration, and water quality can affect:

• pH drift;
• particulate formation;
• metal-ion interactions;
• microbial control;
• stability during storage;
• compatibility after dilution.

A generic or follow-on manufacturer must control compendial water quality, validated sterilization or aseptic processing, container compatibility, and extractables and leachables. The formulation may look simple, but manufacturing controls are important because the product is administered intravenously to medically fragile patients.

Does AMMONUL contain a preservative?

The commercial presentation is a single-dose sterile product and does not rely on a conventional antimicrobial preservative for multidose use. That approach is commercially relevant because preservative exposure is a concern in neonates and infants. A multidose strategy would create additional regulatory and toxicological burdens and would not necessarily improve the product’s value proposition.

What formulation patents protect AMMONUL?

The principal commercial protection for AMMONUL has historically been regulatory orphan-drug protection, manufacturing know-how, product-specific quality controls, and clinical-use experience rather than a clearly differentiated modern excipient patent estate.

A basic aqueous solution containing sodium phenylacetate and sodium benzoate would generally be vulnerable to design-around strategies if no enforceable formulation patent claims cover concentration, pH, container closure, stability, dilution, or administration parameters. Potential claim categories for a follow-on product include:

Claim category	Potential commercial relevance
Concentration and ratio	Protection for a defined sodium phenylacetate-to-sodium benzoate ratio
pH range	Stability and tolerability claims
Dilution protocol	Claims directed to dextrose concentration, final volume, or infusion time
Low-sodium formulation	Potential protection for replacement counterions or reduced sodium content
Ready-to-use product	Premixed infusion or pharmacy-ready container
Container closure	Low-extractables vial, bag, syringe, or dual-chamber system
Stability	Extended shelf life or post-dilution stability
Manufacturing process	Control of impurities, sterilization, or precipitation
Method of use	Treatment protocols for neonates, renal impairment, or emergency dosing

The practical freedom-to-operate question is whether any live patent claims cover the marketed concentration, formulation, container, or method of use in the relevant jurisdiction. Patent term, terminal disclaimers, assignment history, and Orange Book listings must be reviewed separately from orphan-drug exclusivity.

What is the FDA and Orange Book status of AMMONUL?

AMMONUL is an FDA-approved orphan product. Its labeling establishes the approved indication, dosing framework, preparation requirements, warnings, and storage conditions.[1] The product’s value is concentrated in a narrow rare-disease market rather than a broad hospital segment.

For an abbreviated or follow-on entrant, the relevant regulatory pathways can include:

• ANDA, if the product can demonstrate pharmaceutical equivalence and meet applicable generic requirements;
• 505(b)(2), if the proposed product differs in formulation, presentation, concentration, or administration and relies partly on existing findings;
• a new drug application, if the product introduces a clinically meaningful formulation or delivery system;
• an orphan-drug application, if the product qualifies for an independent orphan designation and approval.

Orange Book analysis should address three separate questions:

1. Whether AMMONUL has listed patents.
2. Whether those patents remain enforceable.
3. Whether the proposed product requires a Paragraph IV certification.

A Paragraph IV challenge could target any listed patent covering formulation, method of use, or product presentation. If no relevant listed patents remain, market entry would depend more heavily on regulatory approval, supply capability, clinical adoption, and any remaining non-patent exclusivity.

When did AMMONUL lose exclusivity?

AMMONUL’s earliest regulatory protection is old relative to current pharmaceutical products. Any original orphan-drug exclusivity associated with the product would have expired years ago, subject to the specific designation and approval dates recorded by FDA. Orphan-drug exclusivity is separate from patent protection and does not create a permanent barrier to generic or 505(b)(2) entry.

The primary current barriers are therefore likely to be:

• technical equivalence for an intravenous product;
• sterile manufacturing capacity;
• clinical risk management;
• supply reliability;
• hospital formulary acceptance;
• limited but concentrated rare-disease demand;
• payer and distributor economics.

A potential entrant should not assume that the absence of active orphan exclusivity eliminates commercial risk. A sterile injectable with a small patient population may have limited competition because the market is difficult to supply profitably, not because it is legally blocked.

What excipient strategies could improve AMMONUL?

1. Reduce sodium exposure

Sodium is a central formulation constraint because both active ingredients are sodium salts. A follow-on product could investigate alternative counterions or a lower-sodium prodrug strategy. The development burden would be substantial because changing the counterion may alter:

• pharmacokinetics;
• conversion to active scavenging species;
• osmolality;
• pH;
• renal clearance;
• tolerability;
• comparability to the approved product.

A lower-sodium product could have clinical value in neonates, patients with fluid restrictions, and patients with renal or cardiac complications. This strategy is more likely to support a 505(b)(2) or new-product pathway than a conventional ANDA.

2. Offer a ready-to-use infusion

AMMONUL requires pharmacy dilution before administration. A ready-to-use bag, prefilled container, or dual-chamber system could reduce preparation time and medication-error risk.

Commercial advantages include:

• fewer manipulation steps;
• reduced calculation errors;
• improved emergency-room and intensive-care workflow;
• lower contamination risk;
• more predictable final concentration;
• reduced pharmacy labor.

The principal technical issues are stability after dilution, bag compatibility, oxygen exposure, light sensitivity, extractables, and shipping weight. A ready-to-use presentation could support formulation and container patents if the development team establishes a defensible stability or packaging advantage.

3. Improve pediatric administration

A pediatric-focused product could use smaller fill volumes, dose-calibrated containers, or a standardized concentration that reduces bedside calculations. The product would need to preserve dose flexibility because patients with urea-cycle disorders vary widely in age, weight, metabolic status, and clinical severity.

Possible delivery formats include:

• small-volume sterile bags;
• pharmacy-prepared syringes;
• dose-banded presentations;
• closed-system transfer-compatible containers;
• barcode-enabled hospital packaging.

A prefilled syringe would require careful assessment of viscosity, pressure, container compatibility, dose accuracy, and infusion-device compatibility.

4. Extend post-dilution stability

The current administration model places pressure on pharmacy operations. A product with validated longer post-dilution stability could be attractive to hospitals that need advance preparation for emergency use.

A stability program should assess:

• assay and degradation products;
• pH;
• osmolality;
• visible and subvisible particles;
• container integrity;
• microbial control;
• compatibility with common infusion bags and tubing;
• storage at refrigerated and room temperatures.

Post-dilution stability claims could create a differentiated product even if the active ingredients and nominal concentration remain unchanged.

5. Develop a low-volume formulation

A more concentrated presentation could reduce fluid burden, but it would increase osmolarity and may worsen venous irritation. The commercial value would depend on the balance between fluid restriction and infusion tolerability.

This strategy requires clinical and formulation evidence on:

• central versus peripheral administration;
• maximum infusion rate;
• final osmolality;
• local tolerability;
• dilution volume;
• emergency dosing practicality.

How strong is the AMMONUL patent estate?

The likely strength of the AMMONUL patent estate is moderate to weak for basic composition claims and potentially stronger for narrow formulation, manufacturing, or presentation claims if any remain live.

Estate component	Likely strength
Active ingredients	Weak, because sodium phenylacetate and sodium benzoate are established compounds
Basic aqueous formulation	Weak unless protected by narrow concentration or pH claims
Orphan-drug exclusivity	Expired or historically limited
Sterile manufacturing process	Potentially moderate if claims are specific and unexpired
Container and presentation	Potentially moderate for differentiated systems
Method of use	Variable; depends on claim scope and remaining term
Trade secrets	Potentially important for process controls and supply reliability
Regulatory know-how	Important in a low-volume sterile injectable market

The most credible defensive moat may be operational rather than purely patent-based. A manufacturer with validated sterile production, reliable raw-material sourcing, and established metabolic-disease distribution can maintain share even when formal exclusivity is limited.

Which companies could challenge AMMONUL?

The most likely challengers are specialized injectable manufacturers, rare-disease companies, and generic firms with sterile manufacturing infrastructure. The market is less attractive to broad generic companies because demand is limited and manufacturing failure carries high clinical and regulatory consequences.

A challenger could pursue one of four models:

1. A conventional equivalent injectable concentrate.
2. A lower-cost sterile generic.
3. A ready-to-use infusion.
4. A lower-sodium or pediatric-optimized 505(b)(2) product.

Potential entrants would assess the product against sodium phenylbutyrate products such as BUPHENYL and newer nitrogen-scavenging therapies. AMMONUL has an emergency intravenous role, while oral products address chronic maintenance. That limits direct substitution but creates a portfolio opportunity for a company active in inherited metabolic disease.

What commercial opportunities exist for AMMONUL excipients?

The highest-value opportunities are likely to be formulation-enabled products rather than commodity excipients.

Hospital workflow opportunity

A premixed, ready-to-administer product could command value through labor savings, reduced preparation risk, and improved availability during hyperammonemic crises.

Pediatric and neonatal opportunity

A preservative-free, low-volume, low-sodium presentation could address the most sensitive patient segment. The development program would need strong safety, compatibility, and dosing support.

Global market opportunity

Markets outside the United States may have limited access to specialized ammonia-scavenging injectables. A stable product with simplified storage and transport could support expansion into jurisdictions with less advanced hospital pharmacy infrastructure.

Licensing opportunity

Licensing targets could include:

• sterile injectable manufacturers with excess capacity;
• container and delivery-system developers;
• excipient suppliers with low-endotoxin or parenteral-grade technologies;
• rare-disease companies with metabolic-disease sales forces;
• regional distributors serving neonatal and genetic-disease centers.

The most defensible licensing package would combine formulation IP, validated stability, regulatory documentation, and manufacturing know-how. A license based only on a basic excipient substitution would have limited value unless it produced a measurable clinical or operational advantage.

What generic entry risks exist for AMMONUL?

Generic entry could reduce price but may not rapidly displace the incumbent. The principal risks are:

• loss of hospital formulary preference;
• tender-based price erosion;
• supply shortages caused by a small number of sterile suppliers;
• Paragraph IV litigation if listed patents remain;
• 505(b)(2) competition from improved presentations;
• substitution by alternative ammonia-scavenging therapies;
• payer pressure in rare-disease procurement.

The most credible launch scenario is a limited number of suppliers competing on reliability, contract pricing, and shortage protection. A low-cost product with unreliable availability would have limited commercial impact because hospitals may retain the incumbent as a supply safeguard.

Key Takeaways

• AMMONUL uses a deliberately simple excipient system centered on water for injection and pH adjustment.
• The major formulation constraints are sodium load, osmolality, dilution requirements, and sterile injectable manufacturing.
• The strongest commercial opportunities are ready-to-use infusions, pediatric presentations, extended post-dilution stability, and lower-sodium alternatives.
• Original orphan-drug protection is not the main current barrier to entry.
• Patent value is more likely to reside in narrow formulation, packaging, manufacturing, or method-of-use claims than in the active ingredients.
• A follow-on product could pursue an ANDA if closely equivalent or a 505(b)(2) pathway if it introduces a meaningful formulation or delivery difference.
• Supply reliability and sterile manufacturing capability may provide a stronger commercial moat than basic composition patents.

FAQs

Can AMMONUL be reformulated without changing the active ingredients?

Yes. A developer could change concentration, pH, dilution format, container, or post-dilution stability while retaining sodium phenylacetate and sodium benzoate. The regulatory pathway would depend on the extent of the change and the evidence required to establish safety, efficacy, and pharmaceutical equivalence.

Would a preservative-free AMMONUL product have a competitive advantage?

The existing single-dose sterile approach already limits preservative exposure. A new product would need to improve another attribute, such as ready-to-use administration, stability, or packaging, to create a meaningful advantage.

Is a ready-to-use AMMONUL bag patentable?

Potentially. Patentability would depend on novelty and non-obviousness in the specific concentration, container, stability period, packaging configuration, or administration method. A generic premixed bag without a technically distinct feature would face a weaker patent position.

Could an excipient reduce AMMONUL infusion pain?

An excipient could affect pH, osmolality, buffering, or local tolerability, but any change would require careful intravenous safety assessment. The product’s sodium-salt chemistry limits how much excipient modification can improve tolerability without creating new compatibility or toxicity concerns.

Does AMMONUL compete directly with oral nitrogen scavengers?

Only partly. AMMONUL is primarily an acute intravenous intervention, while oral sodium phenylbutyrate and glycerol phenylbutyrate products are used for longer-term nitrogen control. They can be complementary in treatment pathways rather than direct substitutes.

References

1. U.S. Food and Drug Administration. (2023). AMMONUL (sodium phenylacetate and sodium benzoate) injection prescribing information. FDA-approved labeling.

2. National Library of Medicine. (2024). AMMONUL: Sodium phenylacetate and sodium benzoate injection. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Food and Drug Administration. (2024). Orphan drug designations and approvals. FDA Office of Orphan Products Development.

5. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding - sterile preparations. United States Pharmacopeial Convention.